Collaborative Drug Discovery
PureTech established the underlying programs and platforms that have resulted in a substantial pipeline comprised of 23 product candidates and one product cleared by the FDA that are being developed internally or by its affiliates.
View our corporate deck.

Internal R&D Programs
PureTech’s internal programs are focused on harnessing the lymphatic system and related immunology mechanisms for the treatment of cancer, immunological, lymphatic, and CNS-related disorders. The lymphatic system serves as a "superhighway" for immune cell trafficking, connects all tissues to regional lymph nodes and is essential for fluid balance.
Affiliate Programs
The affiliates includes 13 clinical-stage product candidates, including one product that has been cleared by the FDA and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programs that have been developed in collaboration with some of the world's leading scientific experts.
Highlighted Programs
Ordered below by PureTech ownership; lines represent the most advanced stage of each product candidate; not comprehensive of preclinical and discovery programs.

Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Product candidate for lymphedema with encouraging in-human pharmacokinetics
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
PureTech is developing LYT-210, an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
Initial Indication(s):
Patient Population:
Pouchitis (70 – 135K)
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Follica is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical indications. Follica’s approach is based on generating an “embryonic window” in adults via a series of skin disruptions, stimulating stem cells causing new hair follicles to grow. It has two clinical-stage programs focusing on androgenetic alopecia and skin rejuvenation.
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
MS (~900K)
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Dementia-related Psychosis (~1.2M),
Pain
Collaborators:
Key Differentiation:
Note: Lines represent the most advanced stage of each product candidate; not comprehensive of preclinical programs.
* Relevant ownership interests for affiliate programs were calculated on a diluted basis (as opposed to a voting basis) as of 30 June 2019 (other than Follica which is as of 19 July 2019, Vedanta which is as of 23 September 2019, and Gelesis which is as of 9 December 2019) including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Vor ownership assumes all future tranches are funded in the Series A financing round, with PureTech investing an additional $0.7 million, Sonde ownership assumes all future tranches are funded in the Series A financing round, and Gelesis ownership assumes all committed tranches are funded in the Series 3 Growth financing round. Karuna ownership is shown on an outstanding share basis, calculated as of 22 January 2020. With respect to internal programs, PureTech owns 100% of LYT-100, and PureTech owns 100% of LYT-200 and LYT-210 subject to certain interests held by the inventors and advisors to those programs.
R PureTech Health has a right to royalty payments as a percentage of net sales
* These product candidates are regulated as devices and their development has been approximately equated to phases of clinical development
** PureTech is not responsible for development of all of these product candidates and FDA-cleared product. For example: Certain of our Affiliates, including Akili, Vor, Karuna, Gelesis, Follica and Vedanta have independent development teams and PureTech does not control the day-to-day development of their respective product candidates. However, with respect to Follica and Vedanta, we exert control through majority stock ownership, board representation, and voting decisions.
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Product candidate for lymphedema with encouraging in-human pharmacokinetics
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
PureTech is developing LYT-210, an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
Initial Indication(s):
Patient Population:
Pouchitis (70 – 135K)
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Follica is developing a regenerative biology platform designed to treat androgenetic alopecia, epithelial aging and other medical indications. Follica’s approach is based on generating an “embryonic window” in adults via a series of skin disruptions, stimulating stem cells causing new hair follicles to grow. It has two clinical-stage programs focusing on androgenetic alopecia and skin rejuvenation.
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
MS (~900K)
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Collaborators:
Key Differentiation:
Initial Indication(s):
Patient Population:
Dementia-related Psychosis (~1.2M),
Pain
Collaborators:
Key Differentiation:
The BIG Idea - Moving medicine forward at PureTech

